New immunotherapy drug shows promise as cancer treatment, research suggests

[ad_1]

oncology.pencis.com/” style=”clear: right; float: right; margin-bottom: 1em; margin-left: 1em;”>

oncology.pencis.com/”>A new class of Conference-registration-euro/”>immunotherapy could offer hope to cancer patients who do not respond to existing treatments, Research suggests.

oncology.pencis.com/”>The study found the drug, called MOv18 IgE, shrank a tumour in a patient with ovarian cancer and reported that it was well tolerated in patients.

oncology.pencis.com/”>The scientists suggest their findings could pave the way for a completely new type of anti-cancer drug for people with Award-call-for-profile/”>Chemotherapy-resistant cancers.

oncology.pencis.com/”>The study by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, and funded by cancer Research UK, tested whether a type of antibody called IgE could be used to treat human cancer.oncology.pencis.com/”/>

oncology.pencis.com/”>The results pave the way to development of an entirely new class of anti-cancer drug for people with Award-call-for-profile/”>Chemotherapy-resistant cancers

                                                         oncology.pencis.com/”>Professor James Spicer, King’s College London

oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy works by stimulating the body’s natural defence system to attack cancer.

oncology.pencis.com/”>Existing antibody drugs used in cancer belong to an antibody type called IgG, but IgE antibodies have not been tested in humans before.

oncology.pencis.com/”>IgE antibodies evolved to target parasites like worms and flukes, and IgG antibodies are involved in attacking bacteria and viruses in the body.

oncology.pencis.com/”>Lead author on the study, Professor James Spicer, professor of experimental cancer medicine at King’s College London and Consultant in Medical oncology at Guy’s and St Thomas’ NHS Foundation Trust (GSTT), said: “IgE is a completely new form of antibody therapy which has shown great promise in this Phase I trial.

oncology.pencis.com/”>“Our findings show that the drug was well tolerated in patients and shrunk a cancerous tumour in a patient with ovarian cancer.

oncology.pencis.com/”>“The results pave the way to development of an entirely new class of anti-cancer drug for people with Award-call-for-profile/”>Chemotherapy-resistant cancers.oncology.pencis.com/”>“The immunology expertise in King’s College London laboratories allowed us to undertake this trial of a completely new form of antibody therapy.”oncology.pencis.com/”/>

oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy has shown enormous potential recently but there are still people with cancer who do not respond to conventional therapy
                                                              oncology.pencis.com/”>Professor Sophia Karagiannis, King’s College London

oncology.pencis.com/”>Co-author Sophia Karagiannis, professor of translational cancer immunology and Conference-registration-euro/”>immunotherapy at King’s College London, said: “Conference-registration-euro/”>immunotherapy has shown enormous potential recently but there are still people with cancer who do not respond to conventional therapy.

oncology.pencis.com/”>“This trial builds on our previous work into the biology of IgE, including experiments in the laboratory suggesting that IgE could be an effective treatment that can offer additional benefits to complement those of established IgG antibodies in the clinic.

oncology.pencis.com/”>“While we are still in the early stage of trials, our next steps will be to evaluate IgE in larger and different groups of patients and to continue studying how IgE antibodies are able to wake up the patient’s immune system to fight different cancers.”

#prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference #CardioOnc #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

[ad_2]

Conference-registration-euro/”>immunotherapy-drug-shows-promise-as.html”>Source link

2023 Healing Hearts Family Bereavement Camp

[ad_1]

cancerCare’s Annual Healing Hearts Family Bereavement Camp Offers a Sea of Support

alt text

This July, families who recently lost a loved one to cancer came together at Memorytown USA in Mount Pocono, PA for cancerCare’s free annual Healing Hearts Family Bereavement Camp. 19 families and close to 40 children and adolescents, ages 4-17, attended this year’s camp from July 14-16.

After families arrived on Friday night, they had the opportunity to gather for dinner, play games, make s’mores and dance to music, courtesy of DJ Angelo. Returning children, once again, sat together at their own table, and made more room for the larger number of children this year. “Seeing that was just amazing because instead of one table, it was two tables,” shared Kathy Nugent, cancerCare’s Senior Director of Regional Programs.

alt text

This year’s camp theme was the ocean, and families made sea-themed memory jars and collages about their loved ones on Saturday. Adults gathered in support groups while children and adolescents gathered in age-specific groups.

Younger children were read “Always Remember,” by Cece Meng, donated by the Light One Little Candle Foundation. They were also taught a dance by cancerCare social worker Nikki Molfetas and decorated canvas bags and memory stones. Meanwhile, older children and teens wrote lyrics to “Hope Floats,” a song composed by Sarah Paul, cancerCare’s Director of Clinical Programs.

The families participated in horseback riding at Mountain Creek Riding Stables, fishing, crafts, lawn games and water activities, which included a sea turtle-themed sprinkler system. They also gathered for a memorial service where the children’s’ groups performed and they were able to honor their loved ones.

alt text

Saturday night, they also participated in karaoke. But “Karaoke was not just karaoke,” noted Cecilia Kuepper, cancerCare‘s Healing Hearts Program Coordinator. “It’s those connections that you make and how the kids are just being kids in that moment.”

On Sunday, adults attended a resilience panel, where people who had experienced similar losses gave the attendees hope and inspiration. “It’s really inspirational for them to listen to these stories because it gives them hope that their children will be okay and that they will be okay,” said Kathy. “They see a life moving forward.”

The children had the opportunity to learn and speak about the different emotions they were experiencing with cancerCare social workers. Younger children released their emotions with kickboxing taught by Kat Morano, cancerCare‘s Education Outreach Coordinator, while older children participated in meditation guided by Nikki. They also built, decorated and flew sea turtle kites.

The weekend ended with a closing ceremony where attendees were invited to share their thoughts and gratitude and received gifts including sea turtle-themed wind chimes and bracelets.

“Having the interactions with other families experiencing loss had a healing effect on my own family,” one attendee shared. “We left camp feeling hope, not hopeless.”

One parent shared, “The kids are more open to talking to us about our loss and how they feel since the camp. I’m glad the camp helped normalize it for us and our children.”

“All the families expressed their gratitude and were so happy to have met others who are experiencing similar loss,” Kathy shared. “There were lots of laughs and tears but everyone went home feeling uplifted.”

alt text

The Healing Hearts Family Bereavement Camp would not be possible without our volunteers, partners and supporters. Special thanks to Eisai, our primary sponsor, as well as our other supporters, including the Lillian Schenck Foundation, Valley Hospital Foundation, DeAnna Stark Pasciuto Memorial Fund – Northern New Jersey Community Foundation and Genmab. We would like to thank the Giving Doll Foundation for the donation of dolls and the Light One Little Candle Foundation for the donation of books for the children. We would also like to thank Memorytown USA for providing excellent services and meals to our families, staff and volunteers as well as Mountain Creek Riding Stables for hosting horseback riding.

Like all of cancerCare‘s services, the Healing Hearts Family Bereavement Camp is made available to families completely free of charge. Please consider making a contribution to help support families coping with the loss of a loved one. You can also contact Kathy Nugent at 201-301-6809 or knugent@cancercare.org should you wish to make a charitable contribution.



[ad_2]

Source link

Enhertu Shows Promise for Several Types of HER2-Positive Cancer

[ad_1]

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>The antibody-drug conjugate Enhertu (trastuzumab deruxtecan), which is currently approved for advanced breast, lung and stomach cancer, is also effective for people with several other types of tumors that express HER2, according to Research presented at the 2023 American Society of Clinical oncology (ASCO) Annual Meeting.

oncology.pencis.com/” target=”_blank”>In the Phase II DESTINY-PanTumor02 study, overall response rates were 45% for ovarian cancer, 50% for cervical cancer and 58% for endometrial but only reached 4% for hard-to-treat pancreatic cancer. Rates were higher for tumors with stronger HER2 expression. A related study saw a 38% response rate for advanced colorectal cancer.

oncology.pencis.com/” target=”_blank”>“HER2 is present in many cancer types, such as breast, gastric, lung, gynecologic and urothelial cancers, and patients with HER2-expressing, hard-to-treat cancers need new treatment options,” lead investigator Funda Meric-Bernstam, MD, of the University of Texas MD Anderson cancer Center, said in an ASCO press release.

oncology.pencis.com/” target=”_blank”>“These results advance our clinical understanding of HER2 expression, reaffirm HER2 as an actionable biomarker across a broad range of tumor types and show that trastuzumab deruxtecan could potentially provide a new treatment option for patients with advanced disease across these tumors.”

oncology.pencis.com/” target=”_blank”>Enhertu, from Daiichi Sankyo and AstraZeneca, is an antibody-drug conjugate, a new type of treatment that uses antibodies to deliver toxic Award-call-for-profile/”>Chemotherapy drugs directly to tumors. Enhertu combines the monoclonal antibody trastuzumab (Herceptin), which targets HER2, with a topoisomerase inhibitor as a payload. Tumors that strongly express HER2—a receptor for a protein that promotes cell growth—are classified as HER2-positive.

oncology.pencis.com/” target=”_blank”>The Food and Drug Administration initially granted accelerated approval of Enhertu for the treatment of inoperable or metastatic HER2-positive breast cancer in 2019. At last year’s ASCO meeting, researchers reported that Enhertu also works well for breast tumors with low HER2 expression, leading to approval for that indication and expanding the eligible patient population. Enhertu is also approved for HER2-positive non-small-cell lung cancer and gastric or gastroesophageal junction cancer. This suggests that people with other types of HER2-expressing tumors could benefit as well.

oncology.pencis.com/” target=”_blank”>The open-label DESTINY-PanTumor02 trial (NCT04482309) enrolled 267 previously treated patients with HER2-expressing locally advanced or metastatic biliary tract, bladder (urothelial), cervical, endometrial, ovarian, pancreatic or other tumors. They either had progressed after at least one systemic treatment or had no available treatment options. Seventy-five patients had tumors classified as IHC 3+ (high HER2 expression), while 125 were classified as IHC 2+ (moderate HER2 expression). The participants received Enhertu at a dose of 5.4 milligrams per kilogram by intravenous infusion every three weeks.

oncology.pencis.com/” target=”_blank”>After a median follow-up period of 9.7 months, objective response rates, indicating tumor shrinkage or remission, varied widely across cancer types and were generally better for tumors with higher HER2 expression:

  • oncology.pencis.com/” target=”_blank”>Endometrial cancer: 58% overall, 85% for IHC 3+, 47% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Cervical cancer: 50% overall, 75% for IHC 3+, 40% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Ovarian cancer: 45% overall, 63% for IHC 3+, 37% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Bladder cancer: 39% overall, 56% for IHC 3+, 35% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Biliary tract cancer: 22% overall, 56% for IHC 3+, 0% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Pancreatic cancer: 4% overall, 0% for IHC 3+, 5% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Other tumor types: 30% overall, 44% for IHC 3+, 19% for IHC 2+.

oncology.pencis.com/” target=”_blank”>Across all tumor types, the median duration of response was 11.8 months, rising to 22.1 months for people with IHC 3+ tumors.

oncology.pencis.com/” target=”_blank”>In a related presentation, researchers reported results from the Phase II DESTINY-CRC02 trial (NCT04744831), showing an overall response rate of 38% for people with locally advanced or metastatic colorectal cancer who were treated with the optimal 5.4 mg/kg dose. Here, too, the response rate was higher for patients with IHC 3+ tumors (47%) versus IHC 2+ tumors (6%). The median duration of response was 5.5 months, the median progression-free survival time was 5.8 months and the median overall survival time was 13.4 months.

oncology.pencis.com/” target=”_blank”>Treatment with Enhertu was generally safe, though side effects were common. The most frequently reported severe (Grade 3 or higher) treatment-related adverse events in DESTINY PanTumor02 were white Blood cell deficiency (19%), Award-nomination/”>Anemia (9%), fatigue (6%) and platelet deficiency (5%). Twenty people (8%) developed treatment-related interstitial lung disease or pneumonitis (lung inflammation). About 12% of participants stopped treatment due to side effects.

oncology.pencis.com/” target=”_blank”>“This study provides data for an unmet need for patients who have exhausted standard therapeutic options with tumors that overexpress HER2 for which no drug is yet approved,” said ASCO expert Bradley McGregor, MD, of the Dana-Farber cancer Institute. “While additional follow-up is needed, there is robust activity across multiple HER2-expressing tumors with over 50% response rate in those with the highest levels of HER2 expression coupled with an encouraging safety profile. Trastuzumab deruxtecan could provide a new treatment option for these patients.”

oncology.pencis.com/” target=”_blank”>Click here to ready the DESTINY-PanTumor02 and DESTINY-CRC02 study abstracts.
Click here for more reports from ASCO 2023.
Click here to learn more about pancancer treatment.


    oncology.pencis.com/” target=”_blank”>Read More About:

    oncology.pencis.com/” target=”_blank”>

  • #antibody-drug conjugate
  •  

  • #biliary tract cancer
  •  

  • #bladder cancer
  •  

  • #cancer treatment
  •  

  • #cervical cancer
  •  

  • #colon cancer
  •  

  • #colorectal cancer
  •  

  • #endometrial cancer
  •  

  • #Enhertu
  •  

  • #ovarian cancer
  •  

  • #pancreatic cancer
  •  

  • #targeted therapy

[ad_2]

Source link

Unraveling the role of core promoter variation in triple-negative breast cancer: Study

[ad_1]

Unraveling the role of core promoter variation in triple-negative breast <a href=cancer: A breakthrough study” title=”Variants in core promoter interfere with the cis–trans interaction and the organization of transcriptional initiation complex, leading to increased or decreased transcription initiation. Green line represents wild-type and red line represents mutant. Credit: Genes & Diseases” width=”357″ height=”271″/>
Variants in core promoter interfere with the cis–trans interaction and the organization of transcriptional initiation complex, leading to increased or decreased transcription initiation. Green line represents wild-type and red line represents mutant. Credit: Genes & Diseases

TNBC is a particularly aggressive subtype of breast cancer, characterized by the absence of three key receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Approximately 10–20% of all breast cancers are TNBC. TNBC patients face a poorer prognosis due to the lack of specific drug targets. Therefore, the discovery of new factors influencing the development and progression of TNBC is crucial for improving patient outcomes.

A study published in Genes & Diseases centered on the core promoter, a DNA region surrounding the transcription start site (TSS), for the potential roles of genetic variation in core promoter in abnormal gene expression in TNBC. Core promoters contain multiple highly conserved cis-motifs interacting with different transcriptional factors like RNA polymerase II, TFIIB, and TFIID.

This interaction forms the transcription initiation complex to regulate transcriptional initiation. Genetic variation in the core promoter sequences could interfere with this interaction therefore the proper organization of the transcriptional initiation complex, causing altered transcription initiation and pathological consequences.

Researchers hypothesized that core promoter in TNBC could be highly mutable in contributing to its abnormal gene expression. To test their theory, they analyzed the genomes of 279 TNBC patients using a method called Exome-based Variant Detection in Core-promoters (EVDC).

After filtering out normal genomic polymorphisms, researchers discovered a staggering 19,427 recurrent somatic variants and 1,694 recurrent germline variants in the core promoters of various genes, many of which are known to be oncogenes and tumor suppressors.

The analysis of RNA-seq data from breast cancer revealed altered gene expression in hundreds of these affected genes, providing substantial evidence that core promoter variation could significantly influence gene expression. The researchers further compared these findings with core promoter variation data from 610 unclassified breast cancers. Interestingly, the core promoter variants in TNBC were highly TNBC-specific, suggesting that these variations could contribute significantly to the unique characteristics of TNBC.

This study makes a clear case that the core promoter is mutable and can significantly contribute to the development of cancer, in particular TNBC. While it sheds light on an entirely new aspect of cancer research, there is still much to uncover.

The complex, dynamic nature of gene expression and the variety of mechanisms that can influence it, including epigenetic modification and variation in distal regulatory regions, means that this is just the beginning. The researchers concluded that core promoter variation could provide a new paradigm for studying the mechanisms behind abnormal gene expression in cancer.

While this study focused on TNBC, future research could potentially uncover similar roles of core promoter variation in other types of cancer, leading to even broader applications for cancer detection and treatment.

More information:
Teng Huang et al, Etiological roles of core promoter variation in triple-negative breast cancer, Genes & Diseases (2022). DOI: 10.1016/j.gendis.2022.01.003

Provided by
Chongqing Medical University

Citation:
Unraveling the role of core promoter variation in triple-negative breast cancer: Study (2023, July 25)
retrieved 26 July 2023
from https://medicalxpress.com/news/2023-07-unraveling-role-core-variation-triple-negative.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



[ad_2]

Source link

To manage and reduce the risk of lymphedema, cancer patients are often advised to:



Practice gentle exercise and physical activity to promote lymphatic flow.
Avoid constrictive clothing or jewelry on the affected limb.
Keep the affected limb elevated when resting.
Avoid extreme temperatures (hot baths, saunas) that could worsen swelling.
Maintain good skin hygiene and prevent cuts, scrapes, or burns on the affected limb.
Consult with a certified lymphedema therapist who can provide specialized treatments such as manual lymphatic drainage and compression therapy.

More information – https://oncologyandcancerresearch.blogspot.com/

International Conference on Oncology and Cancer Research:- https://oncology.pencis.com/
Award Nomination link: https://x-i.me/oan
Abstract Submission link: https://x-i.me/srimonco

For Inquiries: oncology@pencis.com

 #shorts #shortsvideo  #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma     #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth  #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors  #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference  #CardioOnc  #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer  #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

CONNECT HERE:-

Facebook  : https://www.facebook.com/Conference-101261931798599
twitter        :https://twitter.com/Samirabellil
pinterest    : https://in.pinterest.com/OncologyandCancerResearch/
Blog          :https://oncologyandcancerresearch.blogspot.com/
tumblr       :https://www.tumblr.com/blog/view/cancer-researcher
instagram :https://www.instagram.com/oncology_researcher/
linkedin     : https://www.linkedin.com/in/cathenna-malia-a20834219/

source

Drug shortages’ effects on cancer research may be felt for years to come

[ad_1]

oncology.pencis.com/” target=”_blank”> The United States is in the midst of some of the worst cancer drug shortages in history, affecting thousands of patients across the country who face delayed or cancelled Award-call-for-profile/”>Chemotherapy appointments. But these shortages aren’t just bad for current patients, experts say; their effects on cancer Research may be felt for years to come.

oncology.pencis.com/” target=”_blank”>The National cancer Institute, the federal government’s main agency for cancer Research and training, told CNN that at least 174 of its 608 trials may be affected by the shortages. However, that number can’t account for other trials that rely on these drugs or possible trials that researchers would like to start but can’t.

oncology.pencis.com/” target=”_blank”>For a mix of complex reasons, many cancer drugs have gone into and out of shortage for years, experts say, but at least 25 are now in shortage, according to the American Society of Health-System Pharmacists. Two in particular — carboplatin and cisplatin — may be hurting Research the most because they are used with such a wide variety of cancers. Cisplatin and other platinum-based drugs are prescribed for 10% to 20% of all cancer patients, according to the National cancer Institute.

oncology.pencis.com/” target=”_blank”>In 2016, when Vice President Joe Biden launched the cancer Moonshot to “accelerate the rate of progress against cancer,” cutting-edge Research was supposed to become a national priority, but with a record number of cancer drugs in shortage, it’s become extremely difficult to conduct even basic Research.

oncology.pencis.com/” target=”_blank”>“With drug shortages, trials have become almost like an impossible task. You start asking yourself, ‘why am I doing this? Should I get a new job?’ ” asked Dr. Shadia Jalal.

oncology.pencis.com/” target=”_blank”>At the Indiana University Melvin and Bren Simon Comprehensive cancer Center, Jalal has overseen several clinical trials that have improved patients’ chances of beating their cancer. She’s also an associate professor of medicine in the Division of Hematology/oncology at IU School of Medicine; she directs Research priorities for Hoosier cancer Research Network, an independent nonprofit that specializes in early-phase multicenter investigator-initiated oncology clinical trials; and she cares for some of the country’s most vulnerable with the Veterans Administration.

oncology.pencis.com/” target=”_blank”>The shortages affect every aspect of her work, and she says they’ve really gotten to her.

oncology.pencis.com/” target=”_blank”>“Honestly, last week, I was so feeling down about it all,” Jalal said. “I was trying to remind myself of why I’m here.”

oncology.pencis.com/” target=”_blank”>Her trials have been able to continue, at least for now, but some researchers haven’t been as fortunate.

oncology.pencis.com/” target=”_blank”>“We’ve heard of institutions shutting down many new clinical trials that involve these drugs in shortage,” said Dr. Mark Fleury, policy principal with the American cancer Society cancer Action Network, a nonprofit, nonpartisan advocacy affiliate of the American cancer Society. Fleury said the issue has not gotten as much attention as the shortages’ effects on individual patients, but it has put the country’s push for better cancer medicine in real jeopardy.

oncology.pencis.com/” target=”_blank”>“Obviously, if you’re not doing the Research for the next best drug, that’s causing ramifications that we may not fully feel for a few years to come,” Fleury said.

oncology.pencis.com/” target=”_blank”>Dmitry Walker, assistant director of pharmacy oncology and investigational drug services at WVU Medicine, said his institution would love to offer a trial for people with bladder cancer using Bacillus Calmette-Guérin (BCG), a treatment that has showed real promise, but a yearslong limited supply makes it impossible.

oncology.pencis.com/” target=”_blank”>BCG is not on the US Food and Drug Administration’s drug shortage list, but the American Society of Health-System Pharmacists lists it as in shortage because drugmaker Merck has instituted tight controls while demand exceeds supply.

oncology.pencis.com/” target=”_blank”>“We’ve actually not been able to open a clinical trial like that, because you have to guarantee you’ll have enough cycles of treatments for them. And we don’t get enough allocation from the manufacturer even to meet our regular patient demand,” Walker said. “I know it’s been very frustrating for our urology physicians, because there’s definitely patients that would benefit from this clinical trial.”

oncology.pencis.com/” target=”_blank”>The National cancer Institute says that none of its clinical trials have had to close or have been put on hold because of the shortages but that some sites may not be able to enroll patients, and not all sites will be affected at the same time.

oncology.pencis.com/” target=”_blank”>“We are in close communication with clinical trials sites to monitor the situation and will provide updates as new data are available,” the institute told CNN in an email.

oncology.pencis.com/” target=”_blank”>Novel drugs typically aren’t the problem for researchers, because pharmaceutical companies can usually supply those to investigators. The problem lies with the drugs that scientists often use in comparison or conjunction with the novel treatment. They’re the medicines that doctors currently use to treat patients, and they’re often generics.

oncology.pencis.com/” target=”_blank”>A survey of major cancer centers published last month found that 93% couldn’t find enough carboplatin, and 70% had cisplatin shortages, according to the National Comprehensive cancer Network. At the beginning of June, the Biden administration worked with China on a special allowance to import cisplatin to help ease the shortage, but the drug remains on the FDA’s shortage list.

oncology.pencis.com/” target=”_blank”>Dr. Lawrence Feldman, a hematology and oncology specialist who has managed cancer drug trials at the University of Illinois Medical Center in Chicago, is recruiting patients for part of a multicenter lung cancer trial that Jalal’s center is also involved in.

oncology.pencis.com/” target=”_blank”>The trial uses carboplatin, which the center ran out of at one point. Swapping in cisplatin, which was more available, would require him to amend the trial.

oncology.pencis.com/” target=”_blank”>“That takes a fair amount of paperwork, and it has to be approved,” Feldman said. It’s time that researchers would rather dedicate to patients, but still, he went ahead with the switch. Just as he was trying to make the change, his center finally got a carboplatin shipment, but he filed the paperwork anyway, in case they have problems again.

oncology.pencis.com/” target=”_blank”>“You never know,” Feldman said. “These drug shortages come and go, and there’s no real rhyme or reason, and there seems to be no rhyme or reason in terms of which institutions have shortages. So it did affect us.”

oncology.pencis.com/” target=”_blank”>The FDA told CNN in an email Thursday that it is “working closely with a number of manufacturers, agencies, and others in the supply chain to understand, mitigate and prevent or reduce the impact of intermittent or increased demand of certain products.” The agency said it is also working across the government to find potential policies that may “ensure meaningful solutions.”

oncology.pencis.com/” target=”_blank”>In one sense, Feldman was lucky because he could swap out drugs. But with cancer, there are often no alternatives.

oncology.pencis.com/” target=”_blank”>Tenuous supplies have made it difficult to plan trials, a process that takes years. What drugs are plentiful now may be in shortage by the time the trial opens. Jalal worries about a trial conducted by a researcher whom she’s mentoring; Jalal was thrilled when it recently opened, but the trial requires a steady supply of carboplatin.

oncology.pencis.com/” target=”_blank”>“I hope to God we can enroll the study on time. We’ve been planning this for two years. I kept thinking to myself, ‘I hope it’s enrolled,’” she said.

oncology.pencis.com/” target=”_blank”>A delay in a trial isn’t just inconvenient. It can mean that the Research becomes irrelevant.

oncology.pencis.com/” target=”_blank”>“The field changes so quickly,” Jalal said. “With a delay, you find yourself asking ‘am I really going to be able to impact things by the time my study finishes?’ “

oncology.pencis.com/” target=”_blank”>Experts say cancer drug shortages probably won’t get better any time soon, and that’s be a big concern for the US, since it means denying help to people who could benefit from participating in these trials.

oncology.pencis.com/” target=”_blank”>“It’s honestly very, very stressful, and just taking care of people with cancer is already really stressful,” Jalal said. “I can’t imagine being a cancer patient right now. It’s very terrifying.”

#prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma     #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth  #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors  #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference  #CardioOnc  #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer  #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

[ad_2]

cancer.html”>Source link

Immunotherapy side effects



Immunotherapy has revolutionized cancer treatment, offering new hope and improved outcomes for many patients. However, like all medical treatments, it can have side effects. The side effects of immunotherapy can vary depending on the specific type of immunotherapy used and the individual patient’s response. Here are some common side effects associated with immunotherapy:

Fatigue: Feeling tired or weak is a common side effect of immunotherapy. Fatigue can range from mild to severe and may impact daily activities.

Skin Reactions: Skin-related side effects are relatively common and can include rashes, itching, and blistering. In some cases, patients may develop a condition known as “dermatitis” or “dermatitis-like” reactions.

Flu-like Symptoms: Some patients may experience flu-like symptoms, including fever, chills, muscle aches, and headaches.

Gastrointestinal (GI) Issues: Immunotherapy can cause various GI problems, such as diarrhea, nausea, vomiting, and loss of appetite.

Pneumonitis: This is an inflammation of the lungs, which can cause cough, shortness of breath, and difficulty breathing.

Hepatitis: Inflammation of the liver (hepatitis) is another potential side effect of immunotherapy.

Thyroid Problems: Immunotherapy can sometimes affect the thyroid gland, leading to hypothyroidism or hyperthyroidism.

Adverse Immune Reactions: Occasionally, immunotherapy can cause an overactive immune response, leading to autoimmune-like reactions affecting various organs and tissues.

More information – https://oncologyandcancerresearch.blogspot.com/

International Conference on Oncology and Cancer Research:- https://oncology.pencis.com/
Award Nomination link: https://x-i.me/oan
Abstract Submission link: https://x-i.me/srimonco

For Inquiries: oncology@pencis.com

#shorts #shortsvideo #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancer #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference #CardioOnc #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #cancerribbon #cancerjourney

CONNECT HERE:-

Facebook : https://www.facebook.com/Conference-101261931798599
twitter :https://twitter.com/Samirabellil
pinterest : https://in.pinterest.com/OncologyandCancerResearch/
Blog :https://oncologyandcancerresearch.blogspot.com/
tumblr :https://www.tumblr.com/blog/view/cancer-researcher
instagram :https://www.instagram.com/oncology_researcher/
linkedin : https://www.linkedin.com/in/cathenna-malia-a20834219/

source

Liver carcinoma Treatment



Surgery: Surgical removal of the tumor (resection) is an option for early-stage liver carcinoma in patients with sufficient liver function.
Liver transplant: In some cases, a liver transplant may be considered for patients with early-stage liver carcinoma and severe liver damage or cirrhosis.
Ablation and embolization: Techniques like radiofrequency ablation (RFA), microwave ablation (MWA), or transarterial chemoembolization (TACE) may be used to destroy or shrink the tumor.
Targeted therapy and immunotherapy: Drugs that target specific molecules or stimulate the immune system to fight cancer may be used in advanced cases or when other treatments are not suitable.
Radiation therapy: High-energy beams are directed at the tumor to kill cancer cells or slow their growth.
Supportive care: Palliative care aims to improve the patient’s quality of life and manage symptoms and side effects.

More information – https://oncologyandcancerresearch.blogspot.com/

International Conference on Oncology and Cancer Research:- https://oncology.pencis.com/
Award Nomination link: https://x-i.me/oan
Abstract Submission link: https://x-i.me/srimonco

For Inquiries: oncology@pencis.com

#shorts #shortsvideo #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference #CardioOnc #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

CONNECT HERE:-

Facebook : https://www.facebook.com/Conference-101261931798599
twitter :https://twitter.com/Samirabellil
pinterest : https://in.pinterest.com/OncologyandCancerResearch/
Blog :https://oncologyandcancerresearch.blogspot.com/
tumblr :https://www.tumblr.com/blog/view/cancer-researcher
instagram :https://www.instagram.com/oncology_researcher/
linkedin : https://www.linkedin.com/in/cathenna-malia-a20834219/

source

Oncogenes #cancerresearch



Oncogenes: These are genes that, when mutated or overexpressed, promote abnormal cell growth and contribute to cancer development. Examples include HER2 (human epidermal growth factor receptor 2) in breast cancer and EGFR (epidermal growth factor receptor) in lung cancer. Targeted therapies, such as trastuzumab and gefitinib, respectively, have been developed to specifically inhibit the activity of these oncogenes.       More information – https://oncologyandcancerresearch.blogspot.com/

International Conference on Oncology and Cancer Research:- https://oncology.pencis.com/
Award Nomination link: https://x-i.me/oan
Abstract Submission link: https://x-i.me/srimonco

For Inquiries: oncology@pencis.com

#cancer #oncology #cancerresearch #cancer2023 #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth  #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors  #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference  #CardioOnc  #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer  #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

CONNECT HERE:-

Facebook  : https://www.facebook.com/Conference-101261931798599
twitter        :https://twitter.com/Samirabellil
pinterest    : https://in.pinterest.com/OncologyandCancerResearch/
Blog          :https://oncologyandcancerresearch.blogspot.com/
tumblr       :https://www.tumblr.com/blog/view/cancer-researcher
instagram :https://www.instagram.com/oncology_researcher/
linkedin     : https://www.linkedin.com/in/cathenna-malia-a20834219/

source